ANIX · Anixa Biosciences Inc
United States · RS rating 23 · As of 2026-10-14
| Price | 2.65 USD |
|---|---|
| 1-day change | -0.6% |
| RS rating (overall / 1M / 3M / 12M) | 23 / 57 / 19 / 17 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 24 / 21 / 39 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +12.5% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +49.1% |
| Market cap (USD) | $101.9M |